Brochure
More information from http://www.researchandmarkets.com/reports/2541548/
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market
Analysis to 2022
Description: “PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by
demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as
Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.
Market growth will be driven by the launch of new DMTs, including several oral therapies that will increase overall treatment rates, and novel DMTs, such as siponimod, that specifically target the large population of MS patients in the UK who have a progressive MS subtype. However, a high rate of generic substitution once key branded products go off patent is an important barrier that limits the market size.
Scope
- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK Multiple Sclerosis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2012-2022 in the UK
Contents: 1 Tables & Figures 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 3 Disease Overview
3.1 Etiology and Pathophysiology 3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Classification of Multiple Sclerosis 3.2 Symptoms
3.2.1 Prognosis 3.2.2 Quality of Life
4 Disease Management 4.1 Diagnosis
4.2 Treatment Overview
4.2.1 Management of Acute Relapse
4.2.2 Treatment with Disease-Modifying Therapies 4.2.3 Symptomatic Therapies 4.3 United Kingdom 4.3.1 Diagnosis 4.3.2 Clinical Practice 5 Competitive Assessment 5.1 Overview
5.2 Strategic Competitor Assessment 5.3 Product Profiles – Major Brands
5.3.1 Betaseron/Betaferon (interferon beta-1b) 5.3.2 Avonex (interferon beta-1a)
5.3.3 Rebif (interferon beta-1a)
5.3.4 Copaxone (glatiramer acetate; copolymer-1) 5.3.5 Tysabri (natalizumab)
5.3.6 Gilenya/Imusera (fingolimod; FTY720) 5.3.7 Aubagio (teriflunomide)
5.3.8 Other Disease–Modifying Therapies 6 Opportunity and Unmet Need
6.1 Overview 6.2 Unmet Needs
6.2.1 Currently Available MS Drugs Only Provide Partial Benefits 6.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 6.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 6.2.4 Effective Treatments for Progressive MS Are Still Elusive
6.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 6.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis
6.3 Unmet Needs Gap Analysis 6.4 Opportunities
6.4.1 Treatments for Progressive MS
6.4.2 Targeting Patients with Clinically Isolated Syndrome 7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development 7.2.1 BG-12 (dimethyl fumarate; BG00012) 7.2.2 Lemtrada (alemtuzumab)
7.2.3 Laquinimod (ABR-215062)
7.2.4 Daclizumab High-Yield Process (HYP) 7.2.5 Ocrelizumab (RG1594)
7.2.6 Siponimod (BAF-312) 7.2.7 NU-100 (interferon beta-1b) 7.2.8 Masitinib (AB-1010) 7.2.9 Tcelna (imilecleucel-T) 8 Market Outlook 8.1 United Kingdom 8.1.1 Forecast 8.1.2 Key Events
8.1.3 Drivers and Barriers 9 Appendix 9.1 Bibliography 9.2 Abbreviations 9.3 Methodology 9.4 Forecasting Methodology 9.4.1 Diagnosed MS patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class 9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions 9.4.6 Individual Drug Assumptions 9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in This Report 9.6 Primary Research – Prescriber Survey
9.7 About the Authors 9.7.1 Analysts
9.7.2 Global Head of Healthcare 9.8 About Us
9.9 Contact Us 9.10 Disclaimer 1.1 List of Tables
Table 1: Common Presenting Symptoms of Multiple Sclerosis Table 2: Factors That Can Affect Prognosis in Multiple Sclerosis
Table 3: Revised 2010 McDonald Criteria for the Diagnosis of Multiple Sclerosis Table 4: Treatment Guidelines for Multiple Sclerosis
Table 5: Top Three Disease-Modifying Therapies Prescribed for Multiple Sclerosis by Market Table 6: Pharmacotherapy for Common Multiple Sclerosis Symptoms
Table 7: Disease-Modifying Drugs for the Treatment of Multiple Sclerosis, 2012 Table 8: Product Profile – Betaseron
Table 9: Betaseron/Betaferon SWOT Analysis, 2012 Table 10: Product Profile – Avonex
Table 11: Avonex SWOT Analysis, 2012 Table 12: Product Profile – Rebif Table 13: Rebif SWOT Analysis, 2012 Table 14: Product Profile – Copaxone Table 15: Copaxone SWOT Analysis, 2012 Table 16: Product Profile – Tysabri Table 17: Tysabri SWOT Analysis, 2012 Table 18: Product Profile – Gilenya Table 19: Gilenya SWOT Analysis, 2012 Table 20: Product Profile – Aubagio Table 21: Aubagio SWOT Analysis, 2012
Table 22: Summary of Alternative MS DMTs, 2012
Table 23: Overall Unmet Needs – Current Level of Attainment Table 24: Clinical Unmet Needs – Gap Analysis, 2012
Table 25: Multiple Sclerosis – Phase Pipeline, 2012
Table 26: Comparison of Therapeutic Classes in Development for Multiple Sclerosis, 2012 Table 27: Product Profile – BG-12
Table 28: BG-12 SWOT Analysis, 2012 Table 29: Product Profile – Lemtrada Table 30: Lemtrada SWOT Analysis, 2012 Table 31: Product Profile – Laquinimod Table 32: Laquinimod SWOT Analysis, 2012
Table 33: Product Profile – Daclizumab High-Yield Process Table 34: Daclizumab SWOT Analysis, 2012
Table 35: Product Profile – Ocrelizumab Table 36: Ocrelizumab SWOT Analysis, 2012 Table 37: Product Profile – Siponimod Table 38: Siponimod SWOT Analysis, 2012 Table 39: Product Profile – NU-100 Table 40: NU-100 SWOT Analysis, 2012 Table 41: Product Profile – Masitinib Table 42: Masitinib SWOT Analysis, 2012 Table 43: Product Profile – Tcelna Table 44: Tcelna SWOT Analysis, 2012
Table 45: Sales Forecasts ($m) for Multiple Sclerosis in the United Kingdom, 2012–2022 Table 46: Key Events Impacting Sales for Multiple Sclerosis in the United Kingdom, 2012
Table 47: Multiple Sclerosis Market in the United Kingdom – Drivers and Barriers, 2012 Table 48: Key Launch Dates
Table 49: Key Patent Expiries
Table 50: Physicians Surveyed, By Country 1.2 List of Figures
Figure 1: Accrual of Disability in the Four Subtypes of Multiple Sclerosis Figure 2: Expanded Disability Status Scale (EDSS)
Figure 3: Current Algorithm for the Treatment of MS with Disease-Modifying Therapies
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Multiple Sclerosis, 2012–2022 Figure 5: Sales for Multiple Sclerosis in the United Kingdom by Drug Class, 2012-2022
Ordering: Order Online - http://www.researchandmarkets.com/reports/2541548/
Order by Fax - using the form below
Order by Post - print the order form below and send to Research and Markets,
Guinness Centre, Taylors Lane, Dublin 8, Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Formats
Please select the product formats and quantity you require:
Contact Information
Please enter all the information below in BLOCK CAPITALS
Product Name: PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2541548/
Office Code: SCD2NPGI
Quantity
Electronic (PDF)
-Single User: USD 4995 Electronic (PDF)
-Site License: USD 9990 Electronic (PDF)
-Enterprisewide: USD 14985
Title: Mr Mrs Dr Miss Ms Prof
First Name: Last Name:
Email Address: * Job Title: Organisation: Address: City:
Postal / Zip Code: Country:
Phone Number: Fax Number:
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
Pay by credit card: You will receive an email with a link to a secure webpage to enter yourcredit card details.
Pay by check: Please post the check, accompanied by this form, to: Research and Markets,
Guinness Center, Taylors Lane, Dublin 8, Ireland.
Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083 Bank Address Ulster Bank,
27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
